We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

Fund managers haven’t disclosed any holdings of AVIR yet.

AVIR Hedge Fund Activity: Q1 2026 in Review

127 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2026, worth a combined $323M — up 59% from $203M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AVIR positions and 10 closed out — a net gain of 17 holders — while 39 added to existing stakes and 38 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.4M. The largest seller was BML Capital Management, cutting an estimated $1.98M.

  • 127 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2026, up from 111 in Q4 2025.
  • Funds reported $323M of Atea Pharmaceuticals stock for Q1 2026, up 59% quarter-over-quarter.
  • 27 funds opened new Atea Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Atea Pharmaceuticals buyer in Q1 2026 was Fidelity Investments, an estimated $10.4M added.
  • The largest Atea Pharmaceuticals seller in Q1 2026 was BML Capital Management, an estimated $1.98M sold.

Based on aggregated 13F filings for Q1 2026.